Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000141246
Ethics application status
Approved
Date submitted
2/03/2009
Date registered
6/03/2009
Date last updated
9/05/2024
Date data sharing statement initially provided
9/05/2024
Date results information initially provided
9/05/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
MATES: Maintenance Thalidomide in Mesothelioma Patients. A phase III trial of anti-angiogenic agent Thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy.
Scientific title
MATES: A phase III trial of anti-angiogenic agent Thalidomide in patients with unresectable malignant mesothelioma who are not progressing after first line therapy compared to no additional treatment after chemotherapy to assess the effectiveness of Thalidomide using time to progression.
Universal Trial Number (UTN)
Trial acronym
MATES
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Unresectable malignant mesothelioma 4214 0
Condition category
Condition code
Cancer 4430 4430 0 0
Lung - Mesothelioma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Addition of Thalidomide 6 weeks after the end of first line chemotherapy, involving antifolate (pemetrexed) with or with out platinum combination (4-6 Cycles). Thalidomide will be administered daily until disease progression or a maximim of 1 year. Patients randomised to receive thalidomide will be treated with thalidomide 100 mg (Starting dose) nightly for the first two weeks. If there are no severe side effects the dose will be increased to 200mg nightly. The mode of administration is oral.
Intervention code [1] 3930 0
Treatment: Drugs
Comparator / control treatment
First line chemotherapy only (Duration is not mentioned here as it will vary based on the treating doctors discretion, involving antifolate (pemetrexed) with or with out platinum combination (4-6 cycles).
The first line chemotherapy regimen (i.e. dose and platinum drugs) is up to the health profession's discretion.
Control group
Active

Outcomes
Primary outcome [1] 5312 0
MAintenance Thalidomide in mEsothelioma patientS (MATES) alone: Quality of life using the Quality of life questionnaire C30 (QLQ-C30) and Quality of Life module LC13 (QLM-LC13), the Lung Cancer Symptom Scale (LCSS)- patient scale and the Pt DATA form completed by patients. The Spitzer Quality of Life Index (QLI) and the LCSS-observer scale completed by physicians.
Timepoint [1] 5312 0
Statistical analysis of MATES study will be completed after recruitment and follow-up of 100 patients. During treatment and after treatment quality of life will be assessed every 4 weeks until disease progression.
Secondary outcome [1] 9316 0
Pooled NVALT5/ MATES (The main objective of NVALT 5 study is to evaluate the effect of maintenance by thalidomide in the time to progression (TTP) in patients who did not progress after > or = 4 courses of treatment and pemetrexed +/- platinum. All time dependent end-points will be taken from the date of randomisation. The main objective of MATES is QOL, and TTP is a secondary endpoint. The data from MATES on TTP, progression free survival and toxicity will be pooled with the NVALT-5 study in a prospective meta-analysis of these endpoints): Time to progression will be assessed with CT scans, chest X-rays and other disease evaluation tools.
Timepoint [1] 9316 0
From randomisation until the first observation of disease progression, every 8 weeks.
Secondary outcome [2] 9317 0
Progression free survival will also be assessed with CT scans, chest X-rays and other disease evaluation tools.
Timepoint [2] 9317 0
From randomisation until first observation of disease progression, every 8 weeks or death from any cause.
Secondary outcome [3] 9318 0
Toxicity will be assessed by clinical and laboratory adverse events using Common Toxicity Criteria version 3
Timepoint [3] 9318 0
Toxicity is assessed weekly for first four weeks during treatment and then at the end of cycle every 4 weeks until the end of treatment.
Secondary outcome [4] 9319 0
Prognostic value of biomarkers will be assessed by using survival and volumetric tumour burden.
Timepoint [4] 9319 0
Assessed at the end of cycle every 4 weeks until week 16.
Statistical analysis of pooled NVALT5/MATES study will be completed after recruitment and follow-up of 216 patients. All patients during treatment will have a clinical exam, clinical symptoms/toxicity evaluation and blood analysis every 4 weeks and radiology tests every 8 weeks, after treatment all patients will have 8 weekly radiological tests (CT scans, X-rays) until disease progression.

Eligibility
Key inclusion criteria
- Histologically or cytologically proven diagnosis of malignant mesothelioma of the pleura or peritoneum.
- Presence of at least one target lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > or = 20mm with conventional techniques or as > or = 10 mm with spiral computed tomography (CT) scan.
- Chemotherapy, containing the antifolate (pemetrexed), is required with at least stabilisation or response (Partial response (PR) or Complete Response (CR)) of the disease with a tleast 4 courses of therapy.
- Women of childbearing age must have a negative pregnancy test or must have adequate contraception during the study and for 3 months after cessation of thalidomide.
-Prior surgery or radiotherapy is allowed as long as there was evidence of progression.
- All cytotoxic therapies should be stopped at least 2 weeks before randomisation.
- Palliative radiotherapy to painful lesions or to prevent the development of metastases along biopsy tracks is allowed.
- Performance status according to Eastern Cooperative Oncology Group- World Health Organisation (ECOG WHO) < or = 2 (After palliative measures like pleural drainage)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
-Pre-existing = grade II sensory neuropathy.
-Severe cardiac, pulmonary, metabolic or other serious co-morbid condiotions.
- Pregnant or lactating women are excluded.
- Life expectancy of < 3 months.
- Uncontrolled infections.
- Prior treatment with thalidomide.
- A period of > or = 6 weeks after the end of chemotherapy treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Enrolment and randomisation will be performed centrally by computer.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation by using a randomization table created by a computer sofware.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/02/2009
Actual
1/05/2009
Date of last participant enrolment
Anticipated
Actual
1/12/2009
Date of last data collection
Anticipated
Actual
1/01/2011
Sample size
Target
100
Accrual to date
Final
14
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Recruitment postcode(s) [1] 1418 0
2000
Recruitment postcode(s) [2] 1419 0
2009
Recruitment postcode(s) [3] 1411 0
2031
Recruitment postcode(s) [4] 1408 0
2050
Recruitment postcode(s) [5] 1413 0
2300
Recruitment postcode(s) [6] 1407 0
2340
Recruitment postcode(s) [7] 1412 0
2350
Recruitment postcode(s) [8] 1409 0
2450
Recruitment postcode(s) [9] 1410 0
2750
Recruitment postcode(s) [10] 1417 0
4020
Recruitment postcode(s) [11] 1414 0
4032
Recruitment postcode(s) [12] 1416 0
4102
Recruitment postcode(s) [13] 1415 0
4560

Funding & Sponsors
Funding source category [1] 4595 0
Government body
Name [1] 4595 0
National Health and Medical Research Council
Country [1] 4595 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
6-10 Mallett Street
Camperdown
NSW-2050
Country
Australia
Secondary sponsor category [1] 4144 0
None
Name [1] 4144 0
Address [1] 4144 0
Country [1] 4144 0
Other collaborator category [1] 542 0
Other Collaborative groups
Name [1] 542 0
Dutch Association of Physicians for Pulmonary Diseases (NVALT) Group
Address [1] 542 0
NKI-AVL
POSTBUS 90203
1006 BE Amsterdam
The Netherlands
Country [1] 542 0
Netherlands

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 6472 0
NSW Cancer Institute Ethics Committee
Ethics committee address [1] 6472 0
PO Box 41 Alexandria NSW 1435
Ethics committee country [1] 6472 0
Australia
Date submitted for ethics approval [1] 6472 0
Approval date [1] 6472 0
28/07/2008
Ethics approval number [1] 6472 0
2008C/04/050

Summary
Brief summary
Malignant pleural mesothelioma is a tumour in the lining outside of the lung. This type of tumour is closely linked to exposure to asbestos fibres. The purpose of this study is to determine if treatment with thalidomide for people with malignant pleural mesothelioma will delay the time until the disease gets worse and also if it will keep people feeling better.
Thalidomide was originally used as a sedative during pregnancy in the late 1950s, with detrimental effects on the embryo. However since then, it has been found that thalidomide may delay tumour growth in people with mesothelioma. The formation of new blood vessels (angiogenesis), plays an important role in tumour growth and spread. Thalidomide stops or delays the formation of new blood vessels (anti-angiogenic effect), which may prevent or slow down the return of cancer.
The research is being done because it is not clear if treatment with thalidomide after treatment with pemetrexed can offer better results than the usual care, which is to have no further chemotherapy treatment after treatment with pemetrexed.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35101 0
Address 35101 0
Country 35101 0
Phone 35101 0
Fax 35101 0
Email 35101 0
Contact person for public queries
Name 12448 0
Brooke Wilson
Address 12448 0
National Health and Medical Research Centre (NHMRC) Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown NSW 1450
Country 12448 0
Australia
Phone 12448 0
+61 2 9562 5321
Fax 12448 0
+61 2 9562 5094
Email 12448 0
mates@ctc.usyd.edu.au
Contact person for scientific queries
Name 3376 0
Nick Pavlakis
Address 3376 0
Royal North Shore Hospital, Pacific Highway St Leonards, NSW- 2065
Country 3376 0
Australia
Phone 3376 0
+61 2 9926 5020
Fax 3376 0
+61 2 9438 2604
Email 3376 0
pavlakis@med.usyd.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Study results articleYes Lancet Oncol. 2013 May;14(6):543-51. doi: 10.1016/... [More Details]

Documents added automatically
No additional documents have been identified.